Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2021 | Percentile | Sector n |
|---|---|---|---|---|
| Med Parmasi Group | Pharma | 8.2% | 35th pct | 116 |
| Grasse Pharma Georgia | Pharma | 2.6% | 18th pct | 116 |
| Sando Pharma | Pharma | -4.0% | 9th pct | 116 |
| Pip Company | Pharma | -5.3% | 8th pct | 116 |
| Medimex | Pharma | — | no FY data | 116 |
Percentile is within each company's own sector across the whole FY2021 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2021 | Sando Pharma | Med Parmasi Group | Pip Company | Grasse Pharma Georgia | Medimex |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 10.3% | 41.1% | 33.6% | 2.6% | — |
| EBITDA Margin | -4.0% | 8.2% | -5.3% | 2.6% | — |
| EBITDAR | -182 | 214 | -70 | 36 | — |
| EBITDAR Margin | -3.2% | 8.2% | -3.3% | 2.6% | — |
| EBIT Margin | -4.2% | 6.1% | -5.5% | 2.6% | — |
| Net Profit Margin | -3.6% | 4.3% | 0.5% | -86.4% | — |
| Operating Expense % of Sales | 14.2% | 32.9% | 39.0% | 0.0% | — |
| Returns | |||||
| Return on Assets (ROA) | -24.0% | 5.3% | 0.5% | -7.4% | — |
| Return on Equity (ROE) | -64.9% | 6.0% | N/A | -7.5% | — |
| ROIC [EBIT / Invested Capital] | -47.0% | 9.0% | N/A | 0.2% | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 23.4% | 2.3% | 2.9% | 0.0% | — |
| Debt-to-Equity | 0.63x | 0.03x | -0.07x | 0.00x | — |
| Debt-to-EBITDA | N/A | 0.23x | N/A | 0.00x | — |
| Equity-to-Assets | 37.0% | 88.4% | -41.8% | 98.1% | — |
| Net Debt | 189 | -124 | 46 | N/A | — |
| Cash & Equivalents | 11 | 174 | 16 | N/A | — |
| Total Debt | 199 | 50 | 62 | N/A | — |
| Liquidity & working capital | |||||
| Current Ratio | 2.18x | 11.10x | 0.71x | 51.55x | — |
| Quick Ratio | 2.18x | 9.07x | 0.28x | 37.66x | — |
| Cash Ratio | 0.03x | 0.90x | 0.01x | 0.00x | — |
| Total Current Assets | 773 | 2,144 | 2,147 | 16,317 | — |
| Total Current Liabilities | 354 | 193 | 3,043 | 317 | — |
| Inventory | N/A | 393 | 1,286 | 4,396 | — |
| Trade Receivables | 208 | 597 | 835 | 11,921 | — |
| Trade Payables | 338 | 151 | 2,970 | 317 | — |
| Net Working Capital | 418 | 1,951 | -897 | 16,000 | — |
| Net Working Capital % of Revenue | 7.4% | 74.7% | -42.5% | 1142.6% | — |
| Trade Working Capital | -130 | 839 | -849 | 16,000 | — |
| Trade Working Capital % of Revenue | -2.3% | 32.2% | -40.2% | 1142.6% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | 3.91x | 1.09x | 0.31x | — |
| Days Inventory Outstanding (DIO) | N/A | 93.3 | 334.9 | 1176.1 | — |
| Receivables Turnover | 27.00x | 4.37x | 2.53x | 0.12x | — |
| Days Sales Outstanding (DSO) | 13.5 | 83.5 | 144.4 | 3107.3 | — |
| Payables Turnover | 14.91x | 10.21x | 0.47x | 4.30x | — |
| Days Payable Outstanding (DPO) | 24.5 | 35.7 | 773.4 | 84.8 | — |
| Cash Conversion Cycle | -11.0 days | 141.1 days | -294.2 days | 4198.6 days | — |
| Asset Turnover | 6.59x | 1.22x | 0.98x | 0.09x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | 79 | N/A | -12 | — |
| Free Cash Flow (OCF − Capex proxy) | N/A | 79 | N/A | -12 | — |
| Cash Conversion (OCF / EBITDA) | N/A | 36.9% | N/A | -33.9% | — |
| Dividends Declared | N/A | N/A | N/A | N/A | — |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | — |